Enbrel and Gemzar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Enbrel (etanercept) and Gemzar (gemcitabine hydrochloride). Common drug interactions include cellulitis among females and influenza among males.

The phase IV clinical study analyzes what interactions people have when they take Enbrel and Gemzar. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Enbrel?

Enbrel has active ingredients of etanercept. It is often used in rheumatoid arthritis. eHealthMe is studying from 664,678 Enbrel users. Check the latest studies of Enbrel.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.



On Aug, 04, 2026

13 people who take Enbrel and Gemzar together, and have interactions are studied.

Enbrel and Gemzar drug interactions.

What are the common drug interactions of Enbrel and Gemzar, by gender? *:

female:

  1. Cellulitis (infection under the skin)
  2. Chest pain
  3. Compression fracture (fracture due to pressure caused by injury)
  4. Constipation
  5. Cystocele (a condition that occurs when the tough fibrous wall between a woman's bladder and her vagina is torn by childbirth)
  6. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  7. Diarrhoea
  8. Dizziness
  9. Dysgeusia (disorder of the sense of taste)
  10. Dysphagia (a condition in which swallowing is difficult or painful)

male:

  1. Influenza
  2. Bladder cancer
  3. Arthritis bacterial (form of joint disorder that involves inflammation of one or more joints due to bacterial infection)
  4. Arthropathy
  5. Cardiac failure congestive
  6. Cystitis (inflammation of the wall of the bladder)
  7. Injection site bruising
  8. Injection site erythema (redness at injection site)
  9. Injection site pain
  10. Injection site reaction

What are the common drug interactions of Enbrel and Gemzar, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Gait disturbance
  2. Gastroenteritis clostridial (inflammation of stomach and intestine clostridial)
  3. Gingival pain (gum pain)
  4. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  5. Haemorrhoids (a swollen vein or group of veins in the region of the anus)
  6. Head injury
  7. Headache (pain in head)
  8. Hepatomegaly (abnormal enlargement of the liver)
  9. Hiatus hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm)
  10. Humerus fracture (injury to the upper arm bone)

50-59:

  1. Back pain
  2. Blood glucose increased
  3. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  4. Mobility decreased (ability to move is reduced)
  5. Nausea (feeling of having an urge to vomit)
  6. Retching (strong involuntary effort to vomit)

60+:

  1. Bladder cancer
  2. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
  3. Anaemia (lack of blood)
  4. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  5. Anxiety
  6. Arthralgia (joint pain)
  7. Back pain
  8. Bone disorder
  9. Bone fragmentation
  10. Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)

What are the existing conditions these people have? *

  1. Psoriasis (immune-mediated disease that affects the skin): 3 people, 23.08%
  2. Neoplasm Malignant (cancer tumour): 3 people, 23.08%
  3. Ankylosing Spondylitis (type of arthritis affecting the spine): 2 people, 15.38%
  4. Bladder Cancer: 2 people, 15.38%
  5. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 15.38%
  6. Breast Cancer: 2 people, 15.38%
  7. Osteoporosis (bones weak and more likely to break): 2 people, 15.38%
  8. Metastases To Bone (cancer spreads to bone): 2 people, 15.38%
  9. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 7.69%
  10. Breast Cancer Metastatic: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Enbrel and Gemzar?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Enbrel and Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Enbrel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Enbrel and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gemzar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on etanercept and gemcitabine hydrochloride (the active ingredients of Enbrel and Gemzar, respectively), and Enbrel and Gemzar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: